Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 Million
Cytokinetics closed an underwritten public offering of 11,338,028 shares of its common stock, including the full exercise of the underwriters' option to purchase an additional 1,478,873 shares. The offering was priced at $71.00 per share, resulting in gross proceeds of approximately $805 million before underwriting discounts and commissions. Morgan Stanley, Goldman Sachs & Co. LLC, J.P.
Key figures
- Deal Value Usd
- 805000000
- Offering Price
- 71
- Shares Offered
- 11338028
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.